International Journal of Cardiology Cardiovascular Risk and Prevention最新文献

{"title":"Colchicine therapy in transcatheter aortic valve replacement: Modulating inflammation and outcomes","authors":"Hamza A. Abdul-Hafez ,&nbsp;Ameer Awashra ,&nbsp;Malik Ahmad ,&nbsp;Abdullah Raed Hawawrah ,&nbsp;Bayan Mahafdah ,&nbsp;Mohammed AbuBaha ,&nbsp;Ibrahim Alazizi ,&nbsp;Abdalhakim Shubietah ,&nbsp;Mohamed S. Elgendy ,&nbsp;Ahmed Emara","doi":"10.1016/j.ijcrp.2026.200575","DOIUrl":"10.1016/j.ijcrp.2026.200575","url":null,"abstract":"<div><h3>Background</h3><div>Transcatheter aortic valve replacement (TAVR) is frequently accompanied by inflammation-related complications, including conduction disturbances, atrial fibrillation, and subclinical leaflet thrombosis. Colchicine, with its anti-inflammatory and antithrombotic properties, has emerged as a potential adjunctive therapy to mitigate these post-procedural events. However, its specific role in the TAVR population remains insufficiently defined.</div></div><div><h3>Methods</h3><div>A narrative review approach was used. Searches of PubMed, Scopus, Web of Science, and Google Scholar were performed through September 2025 using terms related to “transcatheter aortic valve replacement,” “TAVR,” and “colchicine.” Randomized trials, observational studies, mechanistic investigations, and guideline documents were screened. Findings were organized thematically to summarize mechanisms, therapeutic rationale, and clinical outcomes.</div></div><div><h3>Results</h3><div>Only one randomized controlled trial and one observational study have directly evaluated colchicine after TAVR. Both demonstrated reductions in inflammatory biomarkers and signals toward improved conduction-related parameters, but clinical endpoints such as pacemaker implantation, sustained arrhythmias, and imaging-confirmed leaflet thrombosis remain insufficiently studied. Mechanistic and perioperative cardiac evidence from non-TAVR settings supports colchicine’s potential by targeting inflammasome activity, microtubule regulation, and early thrombo-inflammatory remodeling.</div></div><div><h3>Conclusions</h3><div>Colchicine is a promising adjunctive strategy for attenuating inflammation-related complications after TAVR. Its multimodal actions align with the pathways implicated in conduction disturbances, atrial fibrillation, and leaflet thrombosis. However, current evidence is preliminary, with only two post-TAVR intervention studies available. Larger trials are needed to determine whether colchicine can translate mechanistic advantages into clinically meaningful improvements in post-TAVR outcomes.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"29 ","pages":"Article 200575"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146057468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are there reliable primary indicators of cardiorespiratory fitness in physically active students?","authors":"Klaus Christian Haggenmüller ,&nbsp;Sebastian Freilinger ,&nbsp;Nils Olson ,&nbsp;Jochen Weil ,&nbsp;Thorsten Schulz ,&nbsp;Renate Maria Oberhoffer ,&nbsp;Barbara Reiner","doi":"10.1016/j.ijcrp.2026.200589","DOIUrl":"10.1016/j.ijcrp.2026.200589","url":null,"abstract":"<div><h3>Background</h3><div>Cardiorespiratory fitness is a central component of preventive sports medical assessments and plays a crucial role in early identification of health risk factors in asymptomatic populations as well as evaluating physical performance. Preventive examinations in sports medicine frequently include the assessment of Handgrip-Strength (HGS), International Physical Activity Questionnaire (IPAQ), or Medical History Interviews (MHI). The aim of this study is to investigate whether one of these can serve as a valid surrogate marker for cardiorespiratory fitness.</div></div><div><h3>Methods</h3><div>A total of 552 university students (mean age: 21.0 ± 3.79 years (37.5% male) underwent a standardized sports medical and motor performance assessment including Cardiopulmonary Exercise Testing (CPET) on a bicycle ergometer, IPAQ, HGS testing, and a structured MHI. Associations between VO₂peak and the proposed surrogate markers were analysed, controlling for sex and body weight.</div></div><div><h3>Results</h3><div>The parameters with the highest explanatory values were HGS (R = 0.439, p &lt; .001) and MHI (R = 0.323, p &lt; .001). The combination of these two parameters (HGS and MHI) had an explanatory value of R² = 0.49 (F(3, 549) = 76.620, p &lt; .001, n = 552).</div></div><div><h3>Conclusions</h3><div>Maximal HGS and MHI showed potential as first-level indicators of cardiovascular fitness and in combination they may support screening in settings with limited resources and can be used for risk group identification. However, for medical applications the Cardiopulmonary Exercise Testing remains indispensable for an accurate and comprehensive assessment of individual cardiovascular fitness.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"29 ","pages":"Article 200589"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146191289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “The association between cognitive function trajectories and all-cause mortality in middle-aged and older Chinese adults with cardiovascular disease: A longitudinal study from CHARLS”","authors":"Palavardhan Peddapalegani ,&nbsp;Raghav Gupta ,&nbsp;Priyanka Bansal ,&nbsp;Pankaj Nainwal ,&nbsp;Hariharan Srinivasan","doi":"10.1016/j.ijcrp.2026.200593","DOIUrl":"10.1016/j.ijcrp.2026.200593","url":null,"abstract":"","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"29 ","pages":"Article 200593"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146191293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Addressing discrepancies in symptom and psychosocial assessments in hypertrophic cardiomyopathy” [Int. J. Cardiol. Cardiovasc. Risk Prev. 27 (2025) 200504]","authors":"Brijesh Sathian,&nbsp;Abdalla Fadul,&nbsp;Yasir Alabbas,&nbsp;Hanadi Al Hamad","doi":"10.1016/j.ijcrp.2026.200628","DOIUrl":"10.1016/j.ijcrp.2026.200628","url":null,"abstract":"","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"29 ","pages":"Article 200628"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific anatomical challenges in TAVR: A closer look at bicuspid aortic valve stenosis","authors":"Pingjun Huang ,&nbsp;Chu Liu ,&nbsp;Jiameng Li ,&nbsp;Lei Li ,&nbsp;Yongquan Sun ,&nbsp;Jiqiang Bu ,&nbsp;Yu Liu ,&nbsp;Tengyue Zhao","doi":"10.1016/j.ijcrp.2026.200591","DOIUrl":"10.1016/j.ijcrp.2026.200591","url":null,"abstract":"<div><h3>Background</h3><div>This paper seeks to examine the findings of the recently published study by Gitto et al., titled \"Clinical Outcomes in Women and Men with Raphe-Type Bicuspid Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Replacement,\" and to conduct a further analysis of the potential influencing factors.</div></div><div><h3>Methods</h3><div>A critical analysis was conducted on this published multicenter registry study, with a focus on the finding that female patients have a higher risk of valve migration after transcatheter aortic valve replacement (TAVR). In-depth discussions were carried out from the perspectives of sex-related anatomical differences of the aorta and device selection.</div></div><div><h3>Results</h3><div>The original study indicated that female patients have a higher risk of post-TAVR valve migration and a lower technical success rate. This analysis suggests that, in addition to the factors mentioned in the original study (e.g., more frequent use of self-expandable valves and intra-annular downsizing), female-specific anatomical characteristics—such as a more horizontal aortic angle, more significant vascular tortuosity, and smaller iliac artery diameter—may jointly affect device delivery, positioning, and release stability, thereby contributing to such outcome disparities. Furthermore, it is recommended that the original study data be further analyzed to evaluate the impact of different types of self-expandable valves (e.g., ACURATE neo2) on valve positioning.</div></div><div><h3>Conclusion</h3><div>In patients with raphe-type bicuspid aortic valve stenosis, sex-related anatomical variations and device selection discrepancies are important factors affecting TAVR outcomes. Future research and technological development should fully take these factors into account to achieve more personalized treatment strategies.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"29 ","pages":"Article 200591"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146191291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal denervation in 2025: long-term evidence supporting sympathetic modulation as a durable strategy for uncontrolled hypertension","authors":"Dominique Stephan ,&nbsp;Emma Morisot ,&nbsp;François Bronner ,&nbsp;Eric Prinz ,&nbsp;Mihaela Calcaianu ,&nbsp;Elena-Mihaela Cordeanu","doi":"10.1016/j.ijcrp.2026.200587","DOIUrl":"10.1016/j.ijcrp.2026.200587","url":null,"abstract":"<div><h3>Background</h3><div>Renal denervation (RDN) has emerged as a promising device-based therapy for uncontrolled hypertension. Recent data from major cardiovascular conferences (EuroPCR, ESH, TCT 2025) provide unprecedented 3-year follow-up evidence on efficacy, safety, and clinical outcomes.</div></div><div><h3>Methods</h3><div>We synthesize key findings from the SPYRAL HTN-ON MED 3-year final report, the Global Symplicity Registry DEFINE (GSR-DEFINE) real-world data, SPYRAL AFFIRM post-approval study, and pooled analyses on acute hypertensive events. Data sources are distiguisehed by level of evidence: randomized sham-controlled trials versus observational registry data.</div></div><div><h3>Results</h3><div>At 3 years, SPYRAL HTN-ON MED demonstrated sustained office systolic blood pressure (SBP) reductions of −18.5 mmHg (RDN) versus −11.7 mmHg (sham), with treatment difference of −6.8 mmHg (p = 0.0002). The GSR-DEFINE registry (n = 3109) showed −20.5 mmHg office SBP reduction at 3 years with progressively increasing effect over time. Pooled analysis revealed a 43% reduction in acute hypertensive events with RDN. No renal artery stenosis or need for reintervention was observed through 3 years.</div></div><div><h3>Conclusion</h3><div>These data support RDN as a potentially durable and safe adjunctive therapy for uncontrolled hypertension in appropriately selected patients. Benefits appear to extend to high-risk populations including patients with diabetes, chronic kidney disease, and prior stroke, though long-term cardiovascular outcome data remain awaited.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"29 ","pages":"Article 200587"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayesian network meta-analysis”","authors":"Yin Jian ,&nbsp;Bin Cao","doi":"10.1016/j.ijcrp.2026.200597","DOIUrl":"10.1016/j.ijcrp.2026.200597","url":null,"abstract":"","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"29 ","pages":"Article 200597"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146191292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden and cross-country inequalities of alcoholic cardiomyopathy: A 1990–2021 analysis","authors":"Mingze Zheng ,&nbsp;Chuang Sun ,&nbsp;Ming Li ,&nbsp;Hongwei Xiang ,&nbsp;He Ren ,&nbsp;Jin Cheng","doi":"10.1016/j.ijcrp.2025.200561","DOIUrl":"10.1016/j.ijcrp.2025.200561","url":null,"abstract":"<div><h3>Introduction</h3><div>Alcoholic cardiomyopathy (ACM) remains a significant yet understudied contributor to global cardiovascular disease, with substantial socioeconomic influences on its epidemiology. This study investigates the global burden, temporal trends, and health inequalities of ACM across 204 countries.</div></div><div><h3>Methods</h3><div>Utilizing the Global Burden of Disease 2021 data (1990–2021), we analyzed age-standardised mortality (ASMR), prevalence (ASPR), and disability-adjusted life years (ASDR) for populations aged ≥15 years. A trend analysis employed the estimated annual percentage change (EAPC), while inequality metrics (Slope Index of Inequality, Concentration Index) assessed socioeconomic disparities using the socio-demographic index (SDI).</div></div><div><h3>Results</h3><div>Globally, ACM caused 47,073 deaths and 2.19 million DALYs in 2021, with an overall decreasing trend (ASMR EAPC: −1.72 %). High-middle SDI regions bore the highest burden (ASDR: 88.27/100,000), particularly Eastern Europe (ASDR: 510.47). We identified a distinct nonlinear relationship with SDI: burden peaked at SDI≈0.75 (p &lt; 0.001), with Eastern Europe showing the steepest rise/decline. Inequality analysis revealed persistent concentration in high-SDI regions (positive concentration indices: 0.51–0.60), though relative inequalities decreased over time. Kazakhstan exhibited the most rapid burden increase (ASMR EAPC: +11.15 %), while Southern Latin America showed maximal decline (ASMR EAPC: −6.69 %).</div></div><div><h3>Conclusions</h3><div>ACM disparities are strongly linked to socioeconomic development, highlighting the need for targeted alcohol policies in high-burden regions and equitable healthcare resource allocation.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200561"},"PeriodicalIF":2.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145925907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Life’s Essential 8 and cardiovascular health: Protective effects on chronic respiratory diseases","authors":"Jianli Ma ,&nbsp;Xiyu Cao ,&nbsp;Zhipeng Ma ,&nbsp;Xiao Liu ,&nbsp;Hualing Wang ,&nbsp;Ke Liu ,&nbsp;Xinyu Li ,&nbsp;Chuantao Zhang","doi":"10.1016/j.ijcrp.2025.200567","DOIUrl":"10.1016/j.ijcrp.2025.200567","url":null,"abstract":"<div><h3>Background</h3><div>Chronic respiratory diseases (CRDs) pose a global health challenge. While individual lifestyle factors are known to influence CRDs risk, the collective role of comprehensive cardiovascular health (CVH) metrics remains less clear. Life’s Essential 8 (LE8) provides a holistic measure of CVH, but its association with CRDs and related mortality is not well-established at the population level.</div></div><div><h3>Methods</h3><div>The observational study was based on the US National Health and Nutrition Examination Survey (NHANES 2007–2018). We adjusted for confounding factors and used survey-weighted logistic regression analysis to assess the association between LE8 and the risk of CRDs and the subtypes. Restricted cubic splines (RCS) evaluated non-linear relationships. Subgroup and sensitivity analyses were also conducted. Cox models investigated LE8’s impact on all-cause and chronic lower respiratory diseases (CLRDs) mortality.</div></div><div><h3>Results</h3><div>The observational study included 30,863 participants. After adjusting for confounders, survey-weighted logistic regression demonstrates a negative association between LE8 and the risk of CRDs and the four subtypes, with emphysema showing the most significant association (OR = 0.96, 95 % CI: 0.95, 0.97, <em>P</em> &lt; 0.001). RCS suggests a non-linear relationship between LE8 and CRDs. Subgroup and sensitivity analyses confirm the robustness of the results. Compared to individuals with low CVH, those with high CVH have lower risks of all-cause mortality and CLRDs mortality (HR = 0.82, 95 % CI: 0.71, 0.93, <em>P</em> = 0.003; HR = 0.27, 95 % CI: 0.08, 0.88, <em>P</em> = 0.030).</div></div><div><h3>Conclusion</h3><div>LE8 inversely correlates with CRDs, and high CVH protects against all-cause and CLRDs mortality.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200567"},"PeriodicalIF":2.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145925908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent device-related thrombosis after left atrial appendage closure with the watchman FLX: A case report and literature review","authors":"Yuemiao Jiao,&nbsp;Yue Yu,&nbsp;Guangyuan Song,&nbsp;Chengqian Yin","doi":"10.1016/j.ijcrp.2025.200527","DOIUrl":"10.1016/j.ijcrp.2025.200527","url":null,"abstract":"<div><h3>Background</h3><div>Left atrial appendage closure (LAAC) effectively lowers stroke risk in atrial-fibrillation (AF) patients who cannot tolerate long-term anticoagulation. Device-related thrombosis (DRT), although infrequent, carries a threefold increase in subsequent embolic events and remains a therapeutic challenge, even with the newer Watchman FLX occluder.</div></div><div><h3>Case summary</h3><div>A 72-year-old woman with paroxysmal AF (CHA₂DS₂-VASc = 5; HAS-BLED = 2) underwent LAAC with a 30 mm Watchman FLX after bleeding-limited warfarin use. She was prescribed dual antiplatelet therapy (DAPT) post-procedure. Eight weeks later, cardiac CT detected a device-surface thrombus; warfarin (INR 2.5–3.0) achieved complete resolution by 7 months. Despite continued anticoagulation, repeat CT at 22 months revealed a larger thrombus. Transesophageal echocardiography confirmed recurrent DRT.</div></div><div><h3>Discussion</h3><div>This case underscores multifactorial DRT pathogenesis: patient-specific hypercoagulability (age, persistent AF, PAI-1 variant), anatomic factors (large LAA, 30 mm device), and premature INR reduction. Current evidence indicates that early hypoattenuation thickening on cardiac CT, peri-device leak, and suboptimal antithrombotic regimens are associated with DRT. Emerging data support CT-based surveillance, individualized anticoagulation—potentially favoring direct oral anticoagulants (DOACs)—and next-generation, endothelialization-oriented device designs.</div></div><div><h3>Conclusion</h3><div>Recurrent, large-burden DRT can occur late after Watchman FLX implantation despite initial thrombus resolution and guideline-directed therapy. Optimal management requires (1) vigilant, multimodality imaging follow-up; (2) stringent, patient-tailored anticoagulation with real-time INR or DOAC level assessment; (3) consideration of genetic or laboratory markers of thrombophilia; and (4) advances in device bioengineering to accelerate endothelial healing. Further studies should refine risk-stratified antithrombotic strategies and validate imaging biomarkers to pre-empt DRT in high-risk LAAC recipients.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200527"},"PeriodicalIF":2.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145925914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}